#	Pagina
attuale pagina	/open-h2020/projects/225747/index.html

Opendata, web and dolomites

FIDA SIGNED

Scale-up of our disruptive antibody analytical platform based in flow-induced dispersion analysis (FIDA) to increase efficiency in the research of new antibodies and vaccines

Total Cost €

EC-Contrib. €

Partnership

Views

FIDA project word cloud

Explore the words cloud of the FIDA project. It provides you a very rough idea of what is the project "FIDA" about.

size 90 native immune artificial days times patented 61 clinical alternatives methodology reactions rate medicine generation 15 2025 10 auto lt preclinical tools materials samples 400m hyper standard fida automation microcapillary diagnostic binding assays 94 prognostic immensely sensitivity biologic single registration versus powerful hospital timeline modern run full simplicity exiting vaccine verify day 8bn hsrs saving device drawbacks platforms patients 3 reagents immunological multiple walk uses simplifies mu vaccines global therapeutic patient mostly quantifying assay treatment 11 standardises completely 16 market away certification minutes antibody characterising follow antibodies arise costly parallel pipeline solution running eliminate drug

Project "FIDA" data sheet

The following table provides information about the project.

Coordinator	FIDA-TECH APS Organization address address: TONSBERGVEJ 49 HIMMELEV city: ROSKILDE postcode: 4000 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Denmark [DK]
Total cost	3˙451˙604 €
EC max contribution	2˙603˙936 € (75%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-EIC-FTI-2018-2020
Funding Scheme	IA
Starting year	2019
Duration (year-month-day)	from 2019-12-01 to 2021-11-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	FIDA-TECH APS FIDA-TECH APS Organization address address: TONSBERGVEJ 49 HIMMELEV city: ROSKILDE postcode: 4000 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (ROSKILDE)	coordinator	1˙394˙621.00
2	FACHHOCHSCHULE NORDWESTSCHWEIZ FACHHOCHSCHULE NORDWESTSCHWEIZ Organization address address: BAHNHOFSTRASSE 6 city: WINDISCH postcode: 5210 website: www.fhnw.ch contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (WINDISCH)	participant	626˙043.00
3	ELVESYS ELVESYS Organization address address: 1-3 BIS RUE ROBERT ET SONIA DELAUNAY city: PARIS postcode: 75011 website: www.elvesys.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	340˙105.00
4	NOVOPTIM SARL NOVOPTIM SARL Organization address address: RUE DE LA LIBERATION 25 city: PARIS postcode: 78350 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	243˙166.00

Map

Project objective

Therapeutic antibodies have rapidly become a major component of modern medicine. The global research antibodies market size is expected to reach €3.8bn by 2025. However, exiting research tools have not been able to eliminate Hyper-Sensitivity Reactions (HSRs) against the biologic drug by the patient’s immune system. HSRs are estimated to occur in 10-15% of hospital patients and can arise for any biologic, mostly antibodies. Antibodies are also important in the R&D of new vaccines. To test vaccines, it is necessary to follow the generation of auto-antibodies to verify that the vaccine is working well. This analysis is done with the same tools used in the antibodies research, and with the same drawbacks: artificial assays based on non-native sample materials. Vaccine R&D is immensely costly: up to €400m over a 11-year timeline is standard for a completely new vaccine and overall failure rate from preclinical through to registration is 94%. FIDA is a patented solution that simplifies and standardises immunological measurements under native conditions. We go from 15 treatment steps on current platforms to a single step with FIDA. FIDA is a powerful methodology for quantifying and characterising antibodies and antibody binding with up to 10-times higher sensitivity than present tools. Assays take 5-20 minutes to run, 90% less than alternatives, with full walk-away automation as-standard. FIDA’s simplicity allows to set-up assays versus new targets within 1 day versus 10 days with current tools. It is based on a microcapillary system that needs <3μl of sample, 16-times less than today’s methods to support parallel testing of multiple early-pipeline drug samples. FIDA uses up to 10μl of standard reagents and running costs are €2.60/assay, saving 61% in operational costs. FIDA focuses on both the global research antibodies market and vaccine R&D market at pre-clinical phase (in which certification as a diagnostic/prognostic device is not needed).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FIDA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FIDA" are provided by the European Opendata Portal: CORDIS opendata.